Latest Muscarinic antagonists Stories

OXFORD, England, May 22, 2013 /PRNewswire/ -- First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle engineering platform Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, has initiated a Phase 2 clinical study with PSX1002 that will assess its effect on...

Phase III Clinical Data Indicate That Indacaterol/Glycopyrronium Has Advantages Over Current Therapies for Efficacy, According to a New Report from Decision Resources BURLINGTON, Mass., May 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European pulmonologists agree that therapies offering a greater effect on quality of life is among the areas of highest unmet...

Data on investigational compounds and an approved product will be presented RIDGEFIELD, Conn., May 17, 2013 /PRNewswire/ -- Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference (ATS 2013) in Philadelphia, PA, May 17 - 22.( )Data will highlight research conducted with a product approved for the treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler®...

SAN DIEGO, May 7, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that results of three studies of MYRBETRIQ(®) (mirabegron) as a treatment for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency were presented in poster sessions at the American Urological Association Annual (AUA) Meeting in San Diego. The first two studies demonstrated the...

MOUNTAIN VIEW, Calif., March 18, 2013 /PRNewswire/ -- TheraVida, Inc., a clinical-stage biopharmaceutical company developing novel combination drug products, presented positive results from a Phase 2 clinical trial of its lead product candidate, Tolenix((TM)) (THVD-201), for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI) at the 28(th) Annual Congress of the European Urological Association (EAU) in Milan, Italy. Tolenix((TM)) is a twice-daily (BID)...

MARKHAM, ON, March 8, 2013 /CNW/ - Astellas Pharma Canada, Inc., the Canadian subsidiary of Tokyo-based Astellas Pharma Inc., announced today Health Canada's approval of Myrbetriq(TM) (mirabegron, extended-release tablets). Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urgency, urgency incontinence and urinary frequency.(1 )Mirabegron, a selective b3-adrenoceptor agonist, is a "first in class" therapeutic agent with a mechanism of action...

Medications that treat overactive bladder (OAB) have notorious side effects such as dry mouth, constipation, and urinary retention. Women’s Excellence in Bladder Control is now trialing and sampling a brand new medication that treats OAB differently. Shelby Township, Michigan (PRWEB) February 20, 2013 Medications that treat overactive bladder (OAB) fall under a class of drugs called “anticholinergics”. Anticholinergic drugs are antispasmodic agents that inhibit the action of...

Scopolamine is an anticholinergic drug with many uses. For example, it prevents nausea, vomiting, and motion sickness. However, scopolamine is re-emerging as an antidepressant, with recent studies showing that scopolamine can rapidly improve mood in depressed patients. In addition, in a new study published in Biological Psychiatry this month by Dr. Moriel Zelikowsky and colleagues at the University of California, Los Angeles, it may also be a possible treatment for anxiety disorders....

MOUNTAIN VIEW, Calif., Jan. 3, 2013 /PRNewswire/ -- TheraVida, Inc., a clinical-stage biopharmaceutical company developing novel combination drug products, announced positive results from a Phase 2 clinical trial of its lead product candidate Tolenix((TM)) (THVD-201) for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). Tolenix((TM)) is a twice-daily (BID) proprietary combination of tolterodine, a muscarinic antagonist used to treat OAB, and pilocarpine,...

TOKYO, November 7, 2012 /PRNewswire/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) confirms the information released today by Novartis Pharma K.K. that it has submitted an application for the registration of QVA149, an investigational fixed dose combination of two long-acting inhaled bronchodilators (indacaterol maleate and glycopyrronium bromide), as a once-daily treatment for chronic obstructive pulmonary disease (COPD) in Japan. CEO of Sosei, Shinichi...